A pair of drugs once hailed as a breakthrough against brain aging has done the opposite of what scientists expected. In a study published in May 2026 in the Proceedings of the National Academy of Sciences, researchers at the University of Connecticut found that the senolytic combination dasatinib plus quercetin (D+Q) stripped away myelin, the fatty insulation that sheathes nerve fibers, in the brains of mice. The damage was concentrated in the corpus callosum, the thick cable of white matter that links the brain’s two hemispheres and keeps thinking fast and coordinated. In other words, the treatment produced the kind of white-matter breakdown it was supposed to prevent.
The finding that upended expectations
Senior author Stephen Crocker and his team administered D+Q to C57BL/6J mice across multiple age groups. Using electron microscopy, they documented significant demyelination in the corpus callosum, with visibly thinned myelin sheaths and disrupted oligodendrocytes, the specialized cells responsible for building and maintaining that insulation. The University of Connecticut described the outcome as unexpected. Crocker’s lab had not anticipated that a therapy designed to clear damaged, senescent cells would itself injure the very cells the brain depends on to keep its wiring intact.
The result is especially jarring because D+Q had built a strong preclinical reputation in the brain. In a doxorubicin-based chemotherapy model, senolytic treatment alleviated cognitive impairment tied to chemo, reducing markers of cellular senescence and tamping down systemic inflammation. In an Alzheimer’s disease mouse model, researchers found that oligodendrocyte progenitor cells clustered around amyloid plaques had taken on senescence-like traits. D+Q selectively cleared those cells, reduced amyloid-beta buildup, and improved cognition. Those results fueled real momentum toward testing D+Q in people with neurodegenerative disease.
That momentum reached a Phase 1 feasibility trial in patients with early symptomatic Alzheimer’s, where investigators confirmed that dasatinib and quercetin could cross into the central nervous system by measuring drug concentrations in both plasma and cerebrospinal fluid. But the trial was designed to assess safety and CNS penetrance, not to look at myelin. No neuroimaging or myelin-specific biomarkers were included.
Why myelin matters so much here
Myelin is not just passive insulation. It is an active, adaptive system. The brain continuously fine-tunes its myelin in response to learning and neural activity, a process researchers call adaptive myelination. When that process breaks down, the consequences are tangible: slower processing speed, difficulty concentrating, memory lapses. These are the hallmark complaints of “chemo brain,” and studies using methotrexate in mouse models have directly linked chemotherapy-related cognitive impairment to disrupted adaptive myelination. The corpus callosum, because of its density and central role in interhemispheric communication, is especially vulnerable.
That is what makes the new finding so uncomfortable. D+Q was being explored partly because chemo brain involves white-matter damage. Now the drug pair itself appears capable of inflicting a strikingly similar injury.
Open questions the study cannot yet answer
This is a single preclinical dataset in one mouse strain, and no independent lab has replicated it. Whether the demyelination would occur at different doses, on different dosing schedules, or in genetically distinct strains remains untested. Long-term behavioral follow-up after D+Q exposure in non-chemotherapy aged mice is also absent from the published data, so the functional consequences of the observed myelin loss are not yet fully characterized.
The Phase 1 Alzheimer’s trial, meanwhile, did not include the kind of imaging or biomarker analysis that could confirm or rule out similar white-matter effects in humans. That gap means the mouse findings cannot be extended to clinical populations with any confidence right now. As of June 2026, no public announcement has been made by any trial sponsor indicating that human D+Q studies have been paused or redesigned in response to the Crocker lab’s findings. Whether ongoing or planned trials will incorporate myelin-specific safety monitoring remains to be seen.
Perhaps the most pressing biological puzzle is why D+Q helped in one context and harmed in another. In the doxorubicin chemo-brain model, the drugs appeared to rescue cognition. In the new study, the same combination damaged the cell population it was expected to protect. One plausible explanation: the drugs’ effects on oligodendrocyte progenitor cells may depend on whether those cells have already been pushed into senescence by chemotherapy. In a chemo-exposed brain, clearing genuinely senescent progenitors could be beneficial. In a brain without that prior insult, D+Q may instead damage healthy or only mildly stressed progenitors that the brain still needs for myelin upkeep. That hypothesis has not been formally tested, and no study has directly compared D+Q’s effects on the corpus callosum in chemotherapy-exposed versus chemotherapy-naive aged mice using the same structural measurements.
What this means for the senolytic pipeline
The strongest evidence in this story sits at opposite ends of the same drug’s track record. Crocker’s PNAS paper provides direct, quantitative electron-microscopy data showing myelin loss in treated animals. That is primary evidence of harm. On the other side, the earlier Alzheimer’s model work and the doxorubicin chemo-brain study provide primary evidence of benefit, with behavioral testing and senescence marker analysis showing cognitive improvement after D+Q.
Neither set of results cancels the other. What they do, taken together, is complicate a narrative that had been moving in one direction. D+Q is not simply protective or simply destructive in the brain. Its effects appear to depend on biological context in ways that researchers are only beginning to map. Until that mapping is further along, and until human myelin data exist, the case for using this drug pair to treat or prevent brain aging carries a new and significant asterisk.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
